Quick Answer
Lyra Therapeutics, Inc. reported Net Income of -$28.92 million for fiscal year 2025.
Lyra Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$28.92M | +69.0% |
| 2024 | -$93.44M | -49.1% |
| 2023 | -$62.68M | -13.4% |
| 2022 | -$55.28M | -27.0% |
| 2021 | -$43.51M | -96.7% |
| 2020 | -$22.13M | -35.7% |
| 2019 | -$16.31M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.98M | +49.6% | +19.5% |
| June 30, 2025 | -$7.44M | +84.5% | +13.0% |
| March 31, 2025 | -$8.55M | +61.9% | +28.0% |
| September 30, 2024 | -$11.87M | +24.1% | +75.3% |
| June 30, 2024 | -$48.13M | -208.2% | -114.4% |
| March 31, 2024 | -$22.45M | -38.1% | -43.5% |
| September 30, 2023 | -$15.65M | -6.0% | -0.2% |
| June 30, 2023 | -$15.62M | -8.7% | +3.9% |
- Lyra Therapeutics, Inc. showed an increase of +69.0% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s net income has declined by 77.4% (from -$16.31 million to -$28.92 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: